Neil Singla, MD
Chief Scientific Officer
Dr. Neil Singla, a board-certified anesthesiologist, is the founder and Chief Scientific Officer of Lotus Clinical Research. Since its inception in 2001, Dr. Singla has served in several roles within the organization including: Research Coordinator, Sub-Investigator, Principal Investigator, Coordinating Investigator, and Chief Scientific Officer.
In his capacity as CSO for Lotus Clinical Research, Dr. Singla has had the opportunity to interact frequently with the FDA’s Analgesics Division on behalf of clients and play a significant role in guiding development strategies for dozens of putative analgesic agents. In the company’s 16-year history, Dr. Singla and Lotus Clinical Research have played a significant role in bringing several molecules to market.
Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country. He currently chairs the Analgesic Clinical Trials Shared/Special Interest Group at both the American Pain Society (APS) and the International Association for the Study of Pain (IASP). He is currently assembling the APS’ second annual Conference on Analgesic Trials (APS-CAT) to be held May 17, 2017, in Pittsburgh, PA with the purpose of helping experts advance best practices in analgesic drug development.
The main focus of Dr. Singla’s academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint analgesic clinical trials can be minimized. As a result, he has developed novel techniques for patient education designed to minimize variability, reduce placebo response, and increase effect size.
Sonia Kaur, DO
Dr. Sonia Kaur is a board-certified physician with over 15 years of experience in analgesic research. She has served as the medical monitor, principal investigator, or sub investigator on over 200 pain studies. In her current capacity, Dr. Kaur provides medical oversight of the Lotus Clinical Research investigative team to ensure proper study conduct and optimal patient safety, and is responsible for liaising with the sponsor’s chief medical officer. She spearheads Lotus Clinical Research’s internal placebo response staff education training program. From 2008-2011, Dr. Kaur served as the chairman of the Glendale Adventist Hospital IRB.
Chief Operating Officer
Anne Arriaga joined Lotus in 2008 and has since assembled a top-quality team of investigators, project managers, and study coordinators. She has managed the clinical operations and execution of over 500 trials, of which over 300 were analgesic trials.
She has a bachelor’s degree in healthcare administration, a degree in nursing, and post graduate training in clinical research management and project management. Prior to joining Lotus, Mrs. Arriaga served for 10 years as the Vice President of Clinical Operations for a 120-bed Phase 1 unit.
Eric Guitard, PMP
Director, Data Management
Eric Guitard is responsible for managing the experienced data management team.
For seven years prior to joining Lotus Clinical Research, he managed the internal CRO functionalities of a biomedical company specializing in pain management. Mr. Guitard was responsible for all project management, data management, vendor management, and clinical program development. He holds a bachelor’s degree in business administration from the University of Montreal and is also a Certified Project Professional Manager from the Project Management Institute.
Director, Quality Operations
Christopher Bowman has over 15 years of experience in clinical research spanning regulatory compliance, quality assurance, and clinical management of Phase I through Phase IV studies. Prior to joining Lotus, he held positions as the Director of Clinical Operations for a clinical and regulatory consulting firm and served as the Director of Quality Operations for a large Phase I-IV clinical trial center. Mr. Bowman has extensive knowledge in Federal Regulations and GCP/ICH guidance with over 12 years conducting GCP compliance audits including investigational sites, sponsors, CROs, clinical vendors, trial master files, IRBs, and FDA readiness visits both in the U.S. and abroad.